-Wall Street Journal Report
Related Posts
RAPT Therapeutics Announces Data, Including Objective Response Rates And Progression-Free Survival, From Its Phase 2 Trial Of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive
Coinbase’s Rivals, FTX And Bittrex, Are ‘Gone’: Analyst Predicts Bullish Growth
Needham analyst John Todaro reiterated a Buy rating on Coinbase Global, Inc (NASDAQ: COIN) with a
Bitcoin, Dogecoin, Ethereum Slide Over Fears Of Mt. Gox’s Billion-Dollar Transfers: King Crypto Consolidation Likely Between $60K-$70K, Says Analyst
The cryptocurrency market edged lower on Tuesday as Mt. Gox's Bitcoin transfer worth billions of dollars kept investors largely averse.